Showing 1 - 3 results of 3 for search 'Alison Forgie', query time: 0.03s Refine Results
  1. 1
    A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors

    A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors by James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong

    Published 2022-04-01
    Get full text
    Article
  2. 2
    498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01

    498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01... by Tae Min Kim, Yung-Jue Bang, Keun-Wook Lee, Patricia LoRusso, Wells Messersmith, Feng Jin, Nehal Lakhani, Alison Forgie, Justin Gainor, Jaume Pons, Hong Wan, Pierre Squifflet, Laura Chow, Philip Fanning, Sophia Randolph, Hyun Chung, Rafael Santana-Davila, Won Seog Kim

    Published 2021-11-01
    Article
  3. 3
    First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

    First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors by Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry

    Published 2022-10-01
    Get full text
    Article

Search Tools: